Notice of Interim Results

RNS Number : 5003L

Instem plc

05 September 2012

 



05 September 2012

Instem plc

("Instem" or the "Company")

Notice of Results

Instem (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, will be announcing its interim results for the six months ended 30 June 2012 on Wednesday 19^th September 2012.

Management will be hosting a presentation for analysts on the day of results. Analysts who wish to attend the presentation should register their interest with Fiona Conroy, contactable at [e-mail] or 020 7653 9847.

For further information, please contact:

Instem plc	[phone]
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Brewin (Nominated Adviser & Broker)	[phone]
Aubrey Powell
Luke Boyce
Newgate Threadneedle	[phone]
Caroline Evans-Jones
Fiona Conroy

About Instem plc

Instem (AIM: INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software. 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.

 

END

 

 

NORDZLFBLKFLBBV